Quantitative MRI can detect subclinical disease progression in muscular dystrophy
- 473 Downloads
Oculopharyngeal muscular dystrophy (OPMD) is a rare autosomal dominant muscular dystrophy with late onset and slow progression. The aim of this study was to compare different methods of quantitative MRI in the follow-up of OPMD to semiquantitative evaluation of MRI images and to functional parameters. We examined 8 patients with genetically confirmed OPMD and 5 healthy volunteers twice at an interval of 13 months. Motor function measurements (MFM) were assessed. Imaging at 1.5 T (Siemens Magnetom Avanto) comprised two axial slice groups at the largest diameter of thigh and calf and included T1w TSE, 2-point Dixon for muscular fat fraction (MFF) and a multi-contrast TSE sequence to calculate quantitative T2 values. T1 images were analyzed using Fischer’s semiquantitative 5-point (0–4) scale. MFM and visual scores showed no significant difference over the study period. Overall T2 values increased in patients over the study period from 49.4 to 51.6 ms, MFF increased from 19.2 to 20.7%. Neither T2 values nor MFF increased in controls. Changes in T2 correlated with the time interval between examinations (r 2 = 0.42). In this small pilot trial, it was shown that quantitative muscle MRI can detect subclinical changes in patients with OPMD. Quantitative MRI might, therefore, be a useful tool for monitoring disease progression in future therapeutic trials.
KeywordsMRI Neuromuscular disease OPMD Follow-up
This study was supported by the Lorenzo Piaggio Foundation, Switzerland. The Institute of Radiology receives an unspecified general grant from Bracco. The sponsor played no role in matters of design, collection, analysis, interpretation of data, and writing the report. The authors would like to thank Tanja Haas for the MRI measurements. We also thank the reviewers for their helpful comments.
Conflicts of interest
The authors declare no conflict of interest.
- 2.Fischmann A, Gloor M, Fasler S, Haas T, Rodoni Wetzel R, Bieri O, Wetzel S, Heinimann K, Scheffler K, Fischer D (2011) Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy. J Neurol 258:1333–1340. doi: 10.1007/s00415-011-5937-9 PubMedCrossRefGoogle Scholar
- 3.Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K, Network TREAT-NMDN (2008) Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 18:894–903. doi: 10.1016/j.nmd.2008.07.003 PubMedCrossRefGoogle Scholar
- 4.Kim HK, Laor T, Horn PS, Wong B (2010) Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol 11:304–311. doi: 10.3348/kjr.2010.11.3.304 PubMedCrossRefGoogle Scholar
- 6.Paradas C, Llauger J, Diaz-Manera J, Rojas-García R, De Luna N, Iturriaga C, Márquez C, Usón M, Hankiewicz K, Gallardo E, Illa I (2010) Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 75:316–323. doi: 10.1212/WNL.0b013e3181ea1564 PubMedCrossRefGoogle Scholar
- 9.Fischer D, Kley RA, Strach K, Meyer C, Sommer T, Eger K, Rolfs A, Meyer W, Pou A, Pradas J, Heyer CM, Grossmann A, Huebner A, Kress W, Reimann J, Schröder RJ, Eymard B, Fardeau M, Udd B, Goldfarb L, Vorgerd M, Olivé M (2008) Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 71:758–765. doi: 10.1212/01.wnl.0000324927.28817.9b PubMedCrossRefGoogle Scholar
- 11.Sinclair C, Morrow J, Fischmann A, Hanna M, Reilly M, Yousry T, Golay X, Thornton J (2011) Skeletal muscle MRI-determined fat fraction and myometric strength in inclusion body myositis and Charcot-Marie-Tooth disease Type 1A. Neuromuscul Disord 21:S5. doi: 10.1016/S0960-8966(11)70014-1 CrossRefGoogle Scholar
- 13.Gaeta M, Scribano E, Mileto A, Mazziotti S, Rodolico C, Toscano A, Settineri N, Ascenti G, Blandino A (2011) Muscle fat fraction in neuromuscular disorders: dual-echo dual-flip-angle spoiled gradient-recalled mr imaging technique for quantification—a feasibility study. Radiology 259:487–494. doi: 10.1148/radiol.10101108 PubMedCrossRefGoogle Scholar